Press Release: European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in May 2013, recommended marketing authorisation for Pomalidomide Celgene (pomalidomide) to treat patients with multiple myeloma.

Multiple myeloma is a rare and incurable cancer of the bone marrow that primarily affects older adults. In Europe, approximately 27,800 new cases are diagnosed each year.

Pomalidomide has a chemical structure that resembles that of thalidomide, a substance that led to the birth of babies with malformed, short or missing limbs, and other severe, life-threatening deformities in the late 1950s and early 1960s.

EMA: Press Release, 31.05.13: European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/2013/05/WC500143828.pdf

---